HC Wainwright Issues Optimistic Outlook for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Harmony Biosciences in a research note issued to investors on Thursday, September 25th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $1.16 per share for the quarter, up from their previous estimate of $1.01. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q3 2026 earnings at $1.25 EPS, FY2028 earnings at $7.21 EPS and FY2029 earnings at $7.43 EPS.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). The company had revenue of $200.49 million during the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. Harmony Biosciences’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS.

A number of other equities analysts have also weighed in on HRMY. Deutsche Bank Aktiengesellschaft lowered their target price on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday. Needham & Company LLC dropped their target price on Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday. Oppenheimer initiated coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 target price for the company. Wall Street Zen raised shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 20th. Finally, The Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a research note on Thursday, July 10th. They issued a “neutral” rating and a $33.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Harmony Biosciences currently has an average rating of “Buy” and an average target price of $45.50.

Harmony Biosciences Stock Up 1.0%

Harmony Biosciences stock opened at $27.04 on Friday. The company’s 50-day moving average price is $35.08 and its two-hundred day moving average price is $33.41. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20. The stock has a market cap of $1.56 billion, a P/E ratio of 8.72, a P/E/G ratio of 0.31 and a beta of 0.84. Harmony Biosciences has a twelve month low of $26.35 and a twelve month high of $41.61.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HRMY. American Century Companies Inc. increased its holdings in Harmony Biosciences by 16.5% in the 2nd quarter. American Century Companies Inc. now owns 1,501,420 shares of the company’s stock worth $47,445,000 after purchasing an additional 212,633 shares in the last quarter. LSV Asset Management raised its position in shares of Harmony Biosciences by 24.6% during the second quarter. LSV Asset Management now owns 1,488,502 shares of the company’s stock worth $47,037,000 after acquiring an additional 293,541 shares during the last quarter. Marshall Wace LLP boosted its holdings in Harmony Biosciences by 36.3% in the second quarter. Marshall Wace LLP now owns 1,209,484 shares of the company’s stock valued at $38,220,000 after acquiring an additional 321,947 shares during the last quarter. Geode Capital Management LLC increased its position in Harmony Biosciences by 9.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,054,348 shares of the company’s stock valued at $33,321,000 after purchasing an additional 88,598 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Harmony Biosciences by 127.6% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock worth $28,658,000 after purchasing an additional 508,498 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.